BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golshani M, Hrdý J. Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination. Vaccines 2022;10:279. [DOI: 10.3390/vaccines10020279] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Muñoz-Jurado A, Escribano BM, Agüera E, Caballero-Villarraso J, Galván A, Túnez I. SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. J Neurol 2022. [PMID: 35788744 DOI: 10.1007/s00415-022-11237-1] [Reference Citation Analysis]
2 Paybast S, Emami A, Baghalha F, Naser Moghadasi A. Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: What neurologists need to know? Mult Scler Relat Disord 2022;65:103960. [PMID: 35763914 DOI: 10.1016/j.msard.2022.103960] [Reference Citation Analysis]
3 Tallantyre EC. Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk - No. Mult Scler 2022;:13524585221091404. [PMID: 35485436 DOI: 10.1177/13524585221091404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]